Book an Appointment

Book Appointment

040 6731 3131

040 - 69097676




aniversary_logo news_logo news_logo
Management Dilemmas in Uro-Oncology

Asian Institute of Nephrology and Urology, Hyderabad cordially invites all Urologists, especially urology residents for conference on "Management Dilemmas in Uro-Oncology"

Date: 23rd February, 2020
Time: 9:00 AM to 5:00 PM

Uro-oncology Doctor 1

Dr. Makarand Kochikar

Consultant Uro Oncologist

Uro-oncology Doctor 2

Dr. Srivatsa N

Consultant Uro Oncologist

Program Schedule

For any queries, call us at: +91 8106255577

Closed Event

Program Schedule

09.00-09.30 : Inauguration by Dr T Subramanyeshwar Rao

Session 1Renal cell Carcinoma

Time Event Doctor
09.30-10.00 Partial Nephrectomy for T2 disease
- Imperative indications
- Permissible margin of clearance and ischemia time
- Oncological and functional out come
Dr. Syed Md Ghouse
10.00-10.30 Role of peri-operative Targeted therapy
- Neoadjuvant therapy in locally advanced disease
- Adjuvant therapy in high risk for recurrence disease
- Current evidence and future
Dr. Makarand Kochikar
10.30-11.00 Current status of Cytoreductive Nephrtectomy (CN)
- Individualized management approach to metastatic RCC
- Who benefits the most from Cytoreductive Nephrectomy?
- Will CN further shrink or synergistic with the advent of immunotherapy?
- Current evidence on CN
Dr. Makarand Kochikar
11.00-11.15 Tea Break

Session 2Bladder and Upper tract urothelial malignancy

Time Event Doctor
11.15-11.45 Restaging TURBT in high risk Non Muscle Invasive Bladder Cancer (NMIBC)?
- Clinical rationale and safety of restaging TURBT
- When it can be avoided?
- Does MRI Bladder with VI-RADS avoid unnecessary restaging of TURBT?
Dr. Rajesh Reddy
11.45-12.15 Neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC)
- Is it Mandatory? Available evidence?
- Is it a overkill in T2 disease
- Proposed risk of upstaging in T3 MIBC nonresponders and its implications
Dr. Srivatsa
12.15-12.45 Controversies in the management of upper tract urothelial carcinoma
- Is tissue biopsy or cytology mandatory before the extirpative surgery?
- Oncological outcomes and selection of patients for kidney sparing surgery?
- Current role of upper urinary tract instillation of topical agents
- Current evidence on peri-operative chemotherapy
Dr. Makarand Kochikar
12.45-13.30 Lunch Break

Session 3Carcinoma Prostate

Time Event Doctor
13.30-14.00 Prebiopsy multiparametric MRI
- Is prebiopsy mpMRI mandatory for all patients with suspected prostate Cancer based on elevated PSA?
- Added value of MRI targeted biopsy and its applicability in Indian scenario
Dr. Srivatsa
14.00-14.30 Localized and Locally advanced carcinoma prostate
- Management options and key factors to select optimal treatment modality
- Rationale and extent of lymph node dissection in intermediate risk localized disease
Dr. Makarand Kochikar
14.30-15.00 Biochemical Failure after radical prostatectomy
- Risk factors of relapse after radical prostatectomy and their impact on further management
- Current evidence on adjuvant vs salvage radiotherapy after radical prostatectomy
- Management of PSA only recurrence and PSA persistence after Radical prostatectomy
Dr. Makarand Kochikar
15.00-15.15 Tea Break
15.15-15.45 Metastatic carcinoma prostate
- Definition and management of oligometastatic disease
- Changing treatment paradigm of metastatic Castrate sensitive prostate carcinoma and current evidence
Dr. Srivatsa
15-45-16.15 Non-metastatic Castrate resistant prostate carcinoma
- Definition and clinical scenarios
- Evolving landscape in the management of nm-CRPC
Dr. Rajesh Reddy
16.15-16.45 Optimizing bone health in carcinoma prostate - when and what to start?
- Bone health assessment
- Options to improvise bone health
Dr. Srivatsa
17.00-19.00 Live operative workshop
Dinner follows